Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
Healthcare
$30.51 +5.50%
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
52W Low $18.85High $27.20
Volume 0.53M
Average 0.38M
Balance Sheet
Inspect the capital base behind the business.
Assets
$139.99M
FY 2025 · Annual
-6.4% YoYLiabilities
$298.95M
FY 2025 · Annual
+5.7% YoYEquity
-$158.95M
FY 2025 · Annual
Balance Sheet
USD
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 26.77M | 30M |
| Short-term Investments | 52.59M | 0 |
| Net Receivables | 7.32M | 12.75M |
| Inventory | 14.41M | 38.48M |
| Other Current Assets | 5.61M | 13.47M |
| Total Current Assets | 106.7M | 94.71M |
| Property, Plant & Equipment (Net) | 35.1M | 36.63M |
| Goodwill | 0 | 0 |
| Intangible Assets | 2.04M | 1.99M |
| Long-term Investments | 0 | 0 |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 5.67M | 6.67M |
| Total Non-current Assets | 42.81M | 45.29M |
| Total Assets | 149.51M | 139.99M |
| Account Payables | 6.19M | 5.87M |
| Short-term Debt | 0 | 0 |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 575K | 470K |
| Other Current Liabilities | 5.42M | 7.59M |
| Total Current Liabilities | 16.59M | 23.73M |
| Long-term Debt | 0 | 9.81M |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 235.14M | 235.84M |
| Total Non-current Liabilities | 266.33M | 275.22M |
| Total Liabilities | 282.92M | 298.95M |
| Common Stock | 1K | 1K |
| Retained Earnings | (138.96M) | (168.78M) |
| Accumulated OCI | 149K | (72K) |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | (133.41M) | (158.95M) |
| Total Debt | 33.1M | 41.47M |
| Net Debt | 6.33M | 11.47M |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $133.0M |
| Short-term Investments | $117.1M |
| Receivables | $20.3M |
| Inventory | $45.4M |
| Other Current | $15.6M |
| Total Current Assets | $331.4M |
| PP&E (Net) | $49.2M |
| Intangible Assets | $1.6M |
| Long-term Investments | $6.3M |
| Other Non-current | $2.6M |
| Total Non-current Assets | $59.6M |
| Total Assets | $391.0M |
Analysis
Selected assets total $391.0M for Latest. The largest visible component is Cash & Equivalents at $133.0M, about 34.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 |
How much cash does ALMR have?
Alamar Biosciences, Inc. (ALMR) reported $30.00M in cash and equivalents in fiscal 2025.
How much debt does ALMR carry?
Alamar Biosciences, Inc. (ALMR) reported $41.47M of total debt, with net debt of $11.47M.
Continue the stock analysis
Jump to another research area for this company.